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Abstract
It is well known that acute challenges with psychostimulants such as amphetamine affect impulsive behavior. We here
studied the pharmacology underlying the effects of amphetamine in two rat models of impulsivity, the 5-choice serial
reaction time task (5-CSRTT) and the delayed reward task (DRT), providing measures of inhibitory control, an aspect of
impulsive action, and impulsive choice, respectively. We focused on the role of cannabinoid CB1 receptor activation in
amphetamine-induced impulsivity as there is evidence that acute challenges with psychostimulants activate the
endogenous cannabinoid system, and CB1 receptor activity modulates impulsivity in both rodents and humans. Results
showed that pretreatment with either the CB1 receptor antagonist/inverse agonist SR141716A or the neutral CB1 receptor
antagonist O-2050 dose-dependently improved baseline inhibitory control in the 5-CSRTT. Moreover, both compounds
similarly attenuated amphetamine-induced inhibitory control deficits, suggesting that CB1 receptor activation by
endogenously released cannabinoids mediates this aspect of impulsive action. Direct CB1 receptor activation by D9-
Tetrahydrocannabinol (D9-THC) did, however, not affect inhibitory control. Although neither SR141716A nor O-2050
affected baseline impulsive choice in the DRT, both ligands completely prevented amphetamine-induced reductions in
impulsive decision making, indicating that CB1 receptor activity may decrease this form of impulsivity. Indeed, acute D9-
THC was found to reduce impulsive choice in a CB1 receptor-dependent way. Together, these results indicate an important,
though complex role for cannabinoid CB1 receptor activity in the regulation of impulsive action and impulsive choice as
well as the opposite effects amphetamine has on both forms of impulsive behavior.
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Introduction
Impulsivity is a multifaceted construct covering various, largely
independent, behavioral measures ranging from impulsive actions,
e.g. disturbed inhibitory control and response inhibition, to impulsive
decisions, e.g. delay aversion [1–4]. Maladaptive impulsivity has
been implicated in a wide range of psychiatric and neurological
disorders, including Attention–Deficit/ Hyperactivity Disorder
(ADHD), bipolar disorder, Parkinson’s disease, and substance use-
related disorders [5]. Unraveling the neurobiology of impulsivity may
allow the development of novel pharmacotherapies to treat
maladaptive impulsivity and is therefore of utmost importance.
Traditionally, studies on impulsivity have primarily focused on the
role of monoamine neurotransmission [4,6]. Interestingly, other
neurotransmitters have also been implicated in impulsivity, including
endogenous cannabinoids [3]. The endogenous cannabinoid system,
named after the fact that it is activated by D9-Tetrahydrocannabinol
(D9-THC), the principle active component of herbal cannabis sativa,
includes at least two G-protein coupled receptors, CB1 and CB2
receptors, and several endogenous ligands including N-arachidonoyl-
ethanolamide (anandamide) and 2-arachidonyl glycerolanandamide
(2-AG) [7–9]. CB1 receptors are the predominant cannabinoid
receptors in the central nervous system with a particular abundance
in brain regions comprising the mesocorticolimbic system [10,11]. In
the brain the endogenous cannabinoid system functions to modulate
synaptic activity by controlling release of virtually all other
neurotransmitters, including GABA, glutamate, and dopamine
(DA) [12]. Considering its abundance and cellular function in the
brain, it is not surprising that the CB1 receptor has been implicated
in regulating many different behaviors, including higher-order
cognitive or executive functions such as attentional processing,
behavioral flexibility, and impulsivity [13–15]. With respect to the
latter, it has been shown that both chronic and acute use of D9-THC
can affect impulsive behavior in humans [16–19]. Moreover, two
recent preclinical studies found evidence for a role for CB1 receptors
in modulating specific aspects of impulsivity, as it was found that the
CB1 receptor antagonists/inverse agonists SR141716A and SLV330
increased inhibitory control in rats [20,21]. In addition, it is note-
worthy that polymorphisms in the CB1 receptor gene (CNR1 gene)
have been linked to impulsivity [22] and the development of ADHD
[23,24], and that ADHD patients were recently found to have
decreased anandamide degradation as compared to healthy control
subjects [25].
Currently, the most widely prescribed drugs to treat ADHD and
maladaptive impulsivity are the psychostimulants methylphenidate
and amphetamine, which enhance monoamine neurotransmission
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[26,27]. Somewhat paradoxically, acute challenges with amphet-
amine decrease inhibitory control in humans and rodents, i.e.
increase impulsive action, at least when operationalized as the
inability to restrain inappropriate behavior [28–34], while
reducing impulsive choice, measured as an intolerance to delayed
gratification or delay aversion [34–39]. These opposite effects of
amphetamine are well-known to depend on enhanced DA
transmission [28,29,31–33,36,38,39]. Nonetheless, interactions
with other neurotransmitter systems including the endogenous
opioid and 5-HT systems [34,38,39] have also been implicated.
Recent studies showed that psychostimulants such as amphet-
amine can acutely affect forebrain endocannabinoid levels [40–
42], although these data remain rather inconclusive considering
the exact direction of the effects. Moreover, CB1 receptor activity
has been shown to modulate amphetamine-induced behavioral
responses [42–47]. This raises the question whether CB1 receptor
activation is involved in the mechanism of action, and possibly
clinical effects, of amphetamine on impulsive behavior. Collec-
tively, these observations do suggest a role for CB1 receptors in
(amphetamine-induced) impulsivity, thereby highlighting the
endocannabinoid system as a potential target for novel anti-
impulsivity pharmacotherapies. To further elucidate this, we here
investigated the role of CB1 receptors in the effects of
amphetamine on impulsive action and impulsive choice, two
behaviorally, neuroanatomically and neurochemically distinct
forms of impulsivity [1]. Specifically, to this aim we employed
systemic drug injections to manipulate impulsive behavior in two
widely employed models of impulsivity, namely the 5-choice serial
reaction time task (5-CSRTT) and delayed reward task (DRT),
measuring impulsive action and impulsive choice, respectively [4].
Results show an important role for cannabinoid CB1 receptor
activity in the regulation of impulsive action and impulsive choice
as well as the opposite effects amphetamine has on both forms of
impulsive behavior, although questions about the underlying
mechanism(s) remain.
Materials and Methods
Subjects
Male Wistar rats were obtained from Harlan CPB (Horst, The
Netherlands). At the start of the experiments animals weighed
approximately 250 grams, and were housed two per cage in
macrolon cages (42.5626.6618.5 cm; length6width6height) un-
der a reversed 12 hr light/dark cycle (lights on at 7.00 p.m.) at
controlled room temperature (2162uC) and relative humidity of
60615%. Animals were maintained at approximately 90% of
their free-feeding weight, starting one week prior to the beginning
of the experiments by restricting the amount of standard rodent
food pellets (Harlan Teklad Global Diet, Blackthorn, UK). Water
was available ad libitum throughout the entire experiment. All
experiments were conducted with the approval of the animal
ethical committee of the VU University Amsterdam, the Nether-
lands (protocol numbers: MFal04-08, ANW08-04, ANW08-05),
and all efforts were made to minimize animal suffering.
Drugs
SR141716A and D9-tetrahydrocannabinol (D9-THC) were
generated and kindly provided by respectively Abbott and Echo
Pharmaceuticals B.V. (both Weesp, the Netherlands). (+)-Amphet-
amine sulfate (OPG, Utrecht, the Netherlands) was dissolved in
sterile saline, whereas SR141716A, O-2050 (Tocris Bioscience,
Bristol, UK), and D9-THC were dissolved in a mixture of ethanol,
Tween80, and sterile saline (ratio 1:1:18) as described before [48].
Drug doses and injection times were based on previous studies
[21,32,36,49,50]. SR141716A and O-2050 were injected 45 min
prior to testing, D9-THC 30 min prior to testing, and amphetamine
20 min prior to testing. Drugs were freshly prepared on each test
day and injected intraperitoneally (i.p.) in a volume of 1 ml/kg
bodyweight according to a Latin square within-subjects design.
Drug tests were conducted on Tuesdays and Fridays with baseline
training sessions on the other weekdays. Prior to the first test day, all
animals had been habituated to i.p. saline injections twice.
Apparatus
Experiments were conducted in identical rat five hole nose poke
operant chambers with stainless steel grid floors (MED-NPW-5L,
Med Associates Inc., St. Albans, VT, USA) housed in sound-
insulating and ventilated cubicles. Set in the curved wall of each
box was an array of five holes. Each nose poke unit was equipped
with an infrared detector and a yellow light emitting diode (LED)
stimulus light. Rodent food pellets (45 mg, Formula P, Bio-Serv,
Frenchtown, USA) could be delivered at the opposite wall via a
dispenser. In addition, a white house light could illuminate the
chamber. A computer equipped with MED-PC version 1.17 (Med
Associates Inc.) controlled experimental sessions and recorded
data. Animals were tested once daily from Monday to Friday,
during the dark phase of the light/dark cycle.
Behavioral procedures
Separate groups of animals (n=14) were trained for each
experiment involving a different drug (combination) and/or task,
unless stated otherwise. Specifically, in total four groups of rats
were used for the experiments involving the 5-CSRTT: one group
for the tests involving SR141716A in combination with amphet-
amine and the tests with SR141716A in combination with
lengthened intertrial interval (ITI), a second group for the dose-
response curve with O-2050, a third group for the tests involving
O-2050 in combination with amphetamine and the tests with
O-2050 in combination with lengthened ITI, and a final group for
the the tests involving D9-THC and the tests with D9-THC in
combination with lengthened intertrial interval (ITI). For the
experiments involving the DRT, three groups of rats were used:
one group for the experiment involving SR141716A in combina-
tion with amphetamine, a second group for the experiment
involving O-2050, and a third group for the dose-response curve
with D9-THC as well as the experiment involving the combination
of D9-THC and SR141716A. For both paradigms similar
habituation and magazine training protocols were followed. This
protocol consisted of a habituation exposure to the operant
chambers for 20 min. with the house light on and the food cup
containing three food pellets during the first session. Subsequently,
in the next two sessions, in total 75 pellets were delivered with an
average delay of 15 seconds (s) to allow the animals to associate the
sound of pellet delivery with reward.
5-Choice Serial Reaction Time Task
A detailed description of the 5-CSRTT behavioral procedure in
our laboratory has been provided previously [32]. In short, rats
were trained to detect and respond to a brief visual stimulus in one
of 5 nose poke units in order to obtain a food reward. Each session
terminated after 100 trials or 30 min, whichever occurred first.
Initially the duration of this stimulus was 32 s and was gradually
decreased to 1 s over sessions until animals reached stable baseline
performance (accuracy .80% correct choice and ,20% errors of
omission). Responding during stimulus presentation or within the
limited hold (LH) period of 2 s was counted as a correct response.
Incorrect responses, premature responses during the fixed 5 s ITI,
and errors of omission (no responses or a response after the LH)
Cannabinoid CB1 Receptors and Impulsivity
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did not lead to the delivery of a food reward and resulted in a 5 s
time-out period during which the houselight was extinguished.
Importantly, when drug effects were studied under conditions with
lengthened ITI duration, only for those specific test days, a fixed
7 s ITI was used. Perseverative responses after correct choice i.e.
repeated responding during stimulus presentation into any
stimulus unit following correct stimulus detection and before
pellet collection, were measured but did not have any pro-
grammed consequences. The number of premature responses was
used as an index for inhibitory control. In addition, the following
other behavioral parameters were measured that reflect task
performance: 1) accurate choice, i.e. percentage correct responses
calculated as [number correct trials/(correct + incorrect trials)]*
100; 2) omission errors, i.e. the total number of omitted trials
during a session; 3) the total number of perseverative responses
after correct choice, measuring aspects of compulsive behavior
[51]; 4) latency to make a correct choice, i.e. the mean time
between stimulus onset and nose poke in the illuminated unit; and
5) feeder latency, i.e. the latency to collect a pellet following correct
choice.
Delayed Reward Paradigm
The delayed reward paradigm used in our laboratory has been
described previously [36]. Briefly, in the final stages of training and
during drug testing, a session was divided into 5 blocks of 12 trials,
each block started with 2 forced choice trials. Each rat received a
left forced and a right forced trial, in random order. In the next 10
trials, the animals had a free choice and both the left and right
units were illuminated. Poking into one position resulted in the
immediate delivery of a small reinforcer (1 food pellet), whereas a
nose poke into the other position resulted in the delivery of a large,
but delayed, reinforcer (4 food pellets). If an animal did not make a
response during this choice phase within 10 s, an intertrial interval
was initiated and the trial was counted as an omission. The
position associated with the small and large reinforcer was always
the same for each individual, and counterbalanced for the group of
rats. Delays for the large reinforcer progressively increased within
a session per block of 12 trials as follows: 0, 5, 10, 20 and 40 s.
Responding into non-illuminated units during the test was
recorded, but had no further programmed consequences. The
behavioral measure to assess task performance, i.e. the percentage
preference for the large reinforcer as a function of delay, was
calculated as the number of choices for the large reinforcer/
(number choices large + small reinforcers) *100. Furthermore, we
calculated the total number of omitted choice trials per block of 10
choice trials within a session.
Statistical analyses
All data were analyzed using NCSS2007 version 07.1.18
(NCSS, LLC., Kaysville, UT, USA). Data were subjected to
repeated measures analyses of variance (ANOVAs) with drug
treatment (5-CSRTT, DRT) and delay to large reinforcer (DRT)
as within subjects variables, except for 5-CSRTT experiments
involving lengthened ITI duration. In that case, data were
subjected to two-way ANOVAs with drug treatment and ITI
duration as within subjects variables. Additional two-way repeated
measures ANOVAs were performed for the 5-CSRTT experi-
ments involving co-administration of SR141716A/O-2050 and
amphetamine, to test for drug-interaction effects on premature
responding as all compounds affected this behavioral measure.
When appropriate, homogeneity of variance across groups was
determined using Mauchly’s tests for equal variances and in
case of violation of homogeneity, Huynh-Feldt epsilon (e) ad-
justed degrees of freedom were applied and the resulting more
conservative probability values depicted and used for subsequent
analyses. In case of statistically significant main effects, further
post-hoc comparisons were conducted using Newman-Keuls
multiple comparison tests. The level of probability for statistically
significant effects was set at 0.05. All graphs were produced using
GraphPad Prism version 5.02 for Windows (GraphPad Software,
San Diego, CA, USA).
Results
Effects of SR141716A on amphetamine-induced
impulsivity
As a first attempt to test the putative involvement of the
endogenous cannabinoid system in amphetamine-induced impul-
sivity, the effects of amphetamine alone and in combination with
the selective CB1 receptor antagonist/inverse agonist SR141716A
(in vitro Ki ,1.8 and 514 nM for CB1 and CB2 receptors,
respectively [52]) were studied, first in the 5-CSRTT. One animal
was excluded from the analyses due to consistent high omission
rates during baseline training and drug testing (.35 omissions/
session). In line with previous reports [28,29,31,32,34], a systemic
injection of amphetamine (0.5 mg/kg) significantly increased
premature responding in the 5-CSRTT (Fig. 1a) and prior
administration of SR141716A dose-dependently attenuated this
effect (F5,60 = 11.57, p,0.001). As summarized in Table 1,
significant treatment effects were also observed on accurate choice
(F5,60 = 11.57, p,0.001), with amphetamine reducing the percent-
age of correct choices and SR141716A dose-dependently reversing
this deteriorating effect. Amphetamine also decreased correct
response latencies (F5,60 = 7.55, p,0.001), and this effect was also
prevented by prior treatment with SR141716A. No significant
effects of any treatment combination were observed for the
number of omission errors (F5,60 = 1.42, NS, e=0.58), persever-
ative responses (F5,60 = 2.66, p,0.1, e=0.39) or feeder latency
(F5,60 = 2.15, p=0.1, e=0.69).
Importantly, in contrast with previous data [21], SR141716A
(1 and 3 mg/kg) by itself did not significantly increase inhibitory
control. However, this discrepancy probably reflected a floor
effect in the current experiment. In the same group of animals, but
tested over four additional test days, 1 mg/kg SR141716A did
significantly reduce the number of premature responses when the
duration of the intertrial interval (ITI) on test days was increased
from 5 s to 7 s (Fig. 1b.; Treatment: F1,13 = 14.98, p=0.002; ITI:
F1,13 = 42.02, p,0.001; Treatment6ITI: F1,13 = 11.85, p=0.004),
a procedural manipulation known to robustly increase impulsivity
in the 5-CSRTT in a baseline (5 s ITI)-dependent way [53,54]. As
shown in Table 2, there further was a significant treatment effect
on the number of omissions made (Treatment: F1,13 = 5.57,
p=0.035; ITI: F1,13 = 0.27, NS; Treatment6ITI: F1,13 = 1.47,
NS), with 1 mg/kg SR141716A significantly increasing the
omission rate. In addition, significant effects of lengthening the
ITI duration were found on correct response latencies (Treatment:
F1,13 = 3.01, NS; ITI: F1,13 = 37.88, p,0.001; Treatment6ITI:
F1,13 = 1.62, NS) and feeder latencies (Treatment: F1,13 = 1.49, NS;
ITI: F1,13 = 10.12, p=0.007; Treatment6ITI: F1,13 = 0.00, NS),
with both types of latencies being shortened by lengthening the
ITI duration, independent of prior drug treatment. No significant
effects of treatment or ITI were found on accurate choice
(Treatment: F1,13 = 1.09, NS; ITI: F1,13 = 3.27, p,0.1; Treatmen-
t6ITI: F1,13 = 0.96, NS) and perseverative responding (Treatment:
F1,13 = 1.03, NS; ITI: F1,13 = 0.10, NS; Treatment6ITI:
F1,13 = 0.46, NS). To control for possible effects of SR141716A
alone on premature responding that remained undetected in
the initial analyses and might hamper the interpretation of the
Cannabinoid CB1 Receptors and Impulsivity
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amphetamine + SR141716A experiment, the dataset was also ana-
lyzed using a two-way repeated measures ANOVA. Results showed
significant overall effects for both amphetamine (F1,12=113.65,
p,0.001) and SR141716A (F2,24=6.04, p=0.007) administration as
well as an interaction effect between the two treatments (F2,24=4.98,
p=0.016), suggesting that the effects of SR141716A on attenuating
premature responding were larger in the presence of amphetamine
compared to its own effect on this parameter.
Since impulsivity is thought to be of a multifaceted nature
covering various behavioral measures with only partially overlap-
ping underlying mechanisms [1–4,55], we next aimed to
determine whether our results in the 5-CSRTT would generalize
to another modality of impulsive behavior, namely impulsive
choice. To that end, the effects of amphetamine alone and in
combination with SR141716A were studied in the DRT. One
animal was removed from the analysis due to a high number of
Table 1. Effects of 0.5 mg/kg amphetamine (AMPH), the CB1 receptor antagonist/inverse agonist SR141716A (SR) and their
combination on measures of attentional function, compulsivity, and motivation in the 5-CSRTT.
Treatment (mg/kg) Accuracy (%) Perseverative responses
Correct response
latency (ms) Omissions Feeder latency (ms)
Vehicle–Vehicle 94.660.9 6.861.6 598622 10.563.1 16326106
Vehicle–SR 1 94.860.8 7.061.0 627634 12.864.0 17276137
Vehicle–SR 3 93.061.5 6.461.1 620631 13.263.6 20386365
AMPH–Vehicle 86.261.4** 6.461.4 534621* 8.562.5 14416101
AMPH–SR 1 88.761.0** 15.665.4 564625 7.661.6 21396342
AMPH–SR 3 89.861.3**# 12.262.4 577620 9.161.4 21686359
In total n = 13 animals were included in the analyses and data depict mean6SEM.
*p,0.05.
**p,0.005 versus Vehicle-Vehicle.
#p,0.05 compared to AMPH-Vehicle.
doi:10.1371/journal.pone.0025856.t001
Figure 1. Pretreatment with the CB1 receptor antagonist/inverse agonist SR141716A attenuates amphetamine-induced impulsive
behaviors. Effects of acute administration of 0.5 mg/kg amphetamine (AMPH), SR141716A (SR), and their combination on the mean (6 SEM)
number of premature responses made in the 5-CSRTT (a,b) and percentage preference for the larger, delayed reinforcer in the DRT (c,d). ITI: intertrial
interval. In total n=13-14 animals were included in the analyses. Drug doses are expressed as mg/kg. **p,0.005 versus respective Vehicle or Vehicle-
Vehicle control; #p,0.05 and ##p,0.005 compared to Amphetamine-Vehicle, ++p,0.005 vs respective ITI 5 s control.
doi:10.1371/journal.pone.0025856.g001
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omissions (.50% of choice trials in each delay block) under
vehicle conditions. As previously observed [34,36–39], amphet-
amine in this task reduced impulsive choice as reflected by an
increased preference for the larger reinforcer over increasing
delays as compared to vehicle treatment (Treatment: F5,60 = 17.30,
p,0.001; Treatment6Delay: F20,240 = 6.21, p,0.001, e=0.63).
Comparable to the 5-CSRTT findings, prior administration of
SR141716A dose-dependently antagonized the effects of amphet-
amine in the DRT, without altering impulsive choice by itself
(Fig. 1c,d). Together, these results indicate that CB1 receptor
activity modulates amphetamine-induced impulsivity in the 5-
CSRTT (impulsive action) as well as the DRT (impulsive choice).
Effects of O-2050 on amphetamine-induced impulsivity
A possible confounding factor of employing SR141716A is this
ligand’s potential inverse agonistic action at CB1 receptors [56]. To
exclude that the observed effects of SR141716A on impulsive
behavior were due to its inverse agonistic properties, and to test the
effects of a structurally unrelated CB1 receptor antagonist, two
separate groups of rats were trained in the 5-CSRTT to test the
effects of O-2050, a neutral, non-selective CB1 receptor antagonist
(in vitroKi,2.5 and 0.2 nM for CB1 and CB2 receptors, respectively
[57]) lacking inverse agonistic properties [49,57,58], alone and in
combination with amphetamine. By itself, similar to the previously
reported effects of SR141716A [21], O-2050 dose-dependently
increased inhibitory control (Fig. 2a; F3,39= 15.82, p,0.001) and
accurate choice (Table 3; F3,39= 4.61, p=0.007). Furthermore, at
the highest dose (3 mg/kg), this neutral CB1 receptor antagonist
increased the number of omissions (F3,39 = 15.82, p,0.001) and
correct response latencies (F3,39 = 19.50, p,0.001). Finally, a
significant overall effect was observed for feeder latencies
(F3,39= 6.97, p,0.001), although further post-hoc tests revealed no
significant dose effects compared to vehicle administration.
For the experiment with amphetamine and O-2050, one rat
needed to be excluded as data on one of the test days was missing for
this animal due to technical problems. Similar to SR141716A,
pretreatment with O-2050 dose-dependently antagonized amphet-
amine-induced increments in premature responding in the 5-CSRTT
(Fig. 2b; F5,60= 21.85, p,0.001, e=0.61). Moreover, similar to the
amphetamine+SR141716A experiment, the lack of effect of O-2050
on inhibitory control under baseline (without amphetamine)
conditions probably reflected a floor effect, as 0.3 mg/kg O-2050
in the same animals was able to reduce premature responding when
in separate test sessions the ITI duration was increased to 7 s (data
not shown; Treatment: F1,13= 7.11, p=0.02; ITI: F1,13= 162.15,
p,0.001; Treatment6ITI: F1,13= 7.70, p=0.02). As in the amphe-
tamine+SR141716A experiment, additional two-way repeated
measures ANOVAs were performed on the amphetamine+O-2050
dataset to control for effects of O-2050 on baseline premature
responding. Results showed significant overall effects for both
amphetamine (F1,12 =34.81, p,0.001) and O-2050 (F2,24 =16.28,
p,0.001) administration as well as an interaction effect between the
two treatments (F2,24= 14.16, p,0.001), suggesting that also
pretreatment with O-2050 had stronger effects on premature
responding combined with amphetamine compared to its own effects
thereon. Significant treatment effects found on other behavioral
parameters in the 5-CSRTT for the amphetamine and O-2050
experiment included accurate choice (Table 3; F5,60= 8.96, p,0.001,
e=0.67), with O-2050 dose-dependently restoring amphetamine-
induced attentional deficits and improving attentional functioning
when administered alone, and number of omissions (F5,60 =13.53,
p,0.001, e=0.47), with 1 mg/kg O-2050 increasing the number of
omissions both when administered alone and in combination with
amphetamine. Possibly related to the latter finding, and another
indication of aspecific somatomotor effects, correct response latencies
were also lengthened by the highest dose of O-2050 (F5,60 =10.64,
p,0.001). No significant treatment effects were observed for
perseverative responses (F5,60 =1.52, NS) and feeder latencies
(F5,60 =2.30, NS, e=0.25).
The effects of amphetamine alone and in combination with O-
2050 were also tested in the DRT (Fig. 2c,d). One animal had to be
excluded from the analysis in this experiment, due to a high
omission rate (.70% omissions in choice trials in each delay block)
on several test days. Again, similar to what was observed for
SR141716A, O-2050 did not significantly alter impulsive choice by
itself, but completely prevented amphetamine-induced reductions
in impulsive choice (Treatment: F5,60 = 5.55, p,0.001; Treatment6
Delay: F20,240= 2.06, p=0.006). Together, these data confirm that
CB1 receptor activity modulates amphetamine-induced impulsive
action as well as impulsive choice. Consequently, the previously
observed effects of SR141716A on impulsivity were likely due to
blockade of endocannabinoid-induced activation of the CB1
receptor rather than inverse agonism at this receptor.
Effects of D9-THC on impulsivity in the 5-CSRTT and DRT
The aforementioned experiments with SR141716A and O-2050
indicate that CB1 receptor activation by endogenous ligands
induces impulsive action as measured in the 5-CSRTT, while
reducing impulsive choice in the DRT. Therefore, we next tested
the effects of direct, agonist-induced CB1 receptor activation on
impulsive behavior in rats. D9-THC was used as an exogenous,
non-selective CB1 receptor agonist (in vitro Ki 5.1 and 3.1 nM for
CB1 and CB2 receptors, respectively [59]), since this compound is
regularly used in clinical studies and has previously been shown to
Table 2. Effects of the CB1 receptor antagonist/inverse agonist SR141716A (SR) on measures of attentional function, compulsivity,
and motivation in the 5-CSRTT under conditions of normal or lengthened intertrial interval (ITI).
Treatment
(mg/kg) ITI (s) Accuracy (%)
Perseverative
responses
Correct response
latency (ms) Omissions Feeder latency (ms)
Vehicle 5 92.661.0 7.261.0 643624 11.562.5 17606140
SR 1 5 92.761.3 7.461.2 656624 16.563.2* 18616163
Vehicle 7 89.161.4 5.962.2 591619++ 11.962.4 1469695+
SR 1 7 91.361.6 7.762.1 624625++ 13.362.9* 1580693+
In total n = 14 animals were included in the analyses and data depict mean6SEM.
*p,0.05 compared to respective Vehicle control.
+p,0.05.
++p,0.005 compared to respective ITI = 5 s control.
doi:10.1371/journal.pone.0025856.t002
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Table 3. Effects of 0.5 mg/kg amphetamine (AMPH), the neutral CB1 antagonist O-2050, and their combinations on measures of
attentional function, compulsivity, and motivation in the 5-CSRTT.
Treatment (mg/kg) Accuracy (%)
Perseverative
responses
Correct response
latency (ms) Omissions Feeder latency (ms)
O-2050 alone
Vehicle 85.661.5 8.662.6 587616 5.960.8 1348683
O-2050 0.3 89.861.3* 7.662.1 599619 6.061.0 1360673
O-2050 1 89.461.6 7.161.8 611624 13.863.8 16206155
O-2050 3 91.562.0** 5.161.0 760624** 32.465.7** 17666122
Amphetamine+O-2050
Vehicle–Vehicle 82.361.5 7.161.6 645632 12.262.3 20596292
Vehicle–O-2050 0.3 84.361.7 9.162.1 672632 14.562.9 19166193
Vehicle–O-2050 1 88.661.8* 7.561.8 790641* 23.163.8* 21156374
AMPH–Vehicle 74.761.8* 5.362.3 615619 9.561.8 17326229
AMPH–O-2050 0.3 79.463.0# 4.061.1 619619 11.863.1 16646236
AMPH–O-2050 1 82.062.8## 6.662.2 701624# 38.365.7**## 444661642
Respectively, n = 14 and n = 13 animals were included in the analyses for O-2050 alone and AMPH+O-2050, and data depict mean6SEM.
*p,0.05.
**p,0.005 versus Vehicle or Vehicle-Vehicle.
#p,0.05.
##p,0.005 compared to AMPH-Vehicle.
doi:10.1371/journal.pone.0025856.t003
Figure 2. Pretreatment with the neutral CB1 receptor antagonist O-2050 also attenuates amphetamine-induced impulsive
behaviors. Effects of acute administration of 0.5 mg/kg amphetamine (AMPH), O-2050, and their combination on the mean (6 SEM) number of
premature responses made in the 5-CSRTT (a,b) and percentage preference for the larger, delayed reinforcer in the DRT (c,d). In total n= 13214
animals were included in the analyses. Drug doses are expressed as mg/kg. *p,0.05 and **p,0.005 versus Vehicle or Vehicle-Vehicle; #p,0.05 and
##p,0.005 compared to Amphetamine-Vehicle.
doi:10.1371/journal.pone.0025856.g002
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acutely affect impulsivity in healthy volunteers [17,18]. In the 5-
CSRTT, one animal was excluded from the analyses due to a high
number of omissions (.40) made under vehicle conditions. Results
showed that acute administration of D9-THC affected premature
responding (F3,36 = 7.60, p,0.001), with post-hoc tests revealing a
significant reduction in impulsive responding following 2 mg/kg
of D9-THC (Fig. 3a). However, as can be seen in Table 4, the
same dose of D9-THC also significantly elevated correct res-
ponse latencies (F3,36 = 12.36, p=0.001, e=0.48) and number of
omissions (F3,36 = 23.47, p,0.001, e=0.45). Hence, the effects on
premature responding probably reflected general disturbance of
task performance rather than a specific reduction in impulsive
behavior. Other behavioral parameters in the 5-CSRTT were not
affected by D9-THC (accurate choice: F3,36 = 1.38, NS; persever-
ative responding: F3,36 = 2.39, p,0.1; feeder latency: F3,36 = 2.06,
NS, e=0.52).
As we observed that the effects of both SR141716A and O-2050
on inhibitory control were particularly pronounced under
lengthened ITI durations, the effects of a low dose (0.5 mg/kg)
of D9-THC were next tested under these conditions on four
additional test days. The same group of rats that was used for the
initial dose-response curve of D9-THC was again tested, and one
Figure 3. The CB receptor agonist D9-Tetrahydrocannabinol does not affect inhibitory control, but reduces impulsive choice. Effects
of acute administration of D9-Tetrahydrocannabinol (THC) on the mean (6 SEM) number of premature responses made in the 5-CSRTT (a,b) and
effects of THC, SR141716A (SR), and their combination on the percentage preference for the larger, delayed reinforcer in the DRT (c,d). ITI: intertrial
interval. In total n=13214 animals were included in the analyses. Drug doses are expressed as mg/kg. *p,0.05 and **p,0.005 versus Vehicle or
Vehicle-Vehicle; #p,0.05 compared to THC-Vehicle, ++p,0.005 vs respective ITI 5 s control.
doi:10.1371/journal.pone.0025856.g003
Table 4. Effects of the CB1 receptor agonist D9-Tetrahydrocannabinol (THC) on measures of attentional function, compulsivity,
and motivation in the 5-CSRTT.
Treatment (mg/kg) Accuracy (%)
Perseverative
responses
Correct response
latency (ms) Omissions Feeder latency (ms)
Vehicle 81.361.7 8.261.2 653616 12.962.3 20916249
THC 0.5 83.961.4 4.961.3 698618 11.661.8 17496151
THC 1 82.361.6 9.762.6 736621 18.662.7 23276355
THC 2 85.662.8 4.261.3 929662** 46.466.4** 30836802
In total n = 13 animals were included in the analyses and data depict mean6SEM.
**p,0.005 versus Vehicle.
doi:10.1371/journal.pone.0025856.t004
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animal (the same one as before) was excluded from the analyses
due to high omission rates under vehicle conditions. As in the
SR141716A experiment (Fig. 1b), lengthening the ITI duration
robustly increased premature responding in this cohort of rats
(Fig. 3b; Treatment: F1,12 = 1.23, NS; ITI: F1,12 = 154.55, p,0.001;
Treatment6ITI: F1,12 = 0.86, NS). Additionally, and somewhat
contrasting the results with SR141716A (Table 2), lengthening the
ITI duration this time also affected accuracy, the number of
omissions made, and perserverative responding whilst not affecting
correct response and feeder latencies (Table 5; accurate choice,
Treatment: F1,12 = 0.10, NS; ITI: F1,12 = 18.27, p=0.001; Treat-
ment6ITI: F1,12 = 0.74, NS; perseverative responding, Treatment:
F1,12 = 0.76, NS; ITI: F1,12 = 10.33, p=0.007; Treatment6ITI:
F1,12 = 2.43, NS; correct response latency, Treatment: F1,12 = 0.12,
NS; ITI: F1,12 = 0.19, NS; Treatment6ITI: F1,12 = 0.08, NS;
omissions, Treatment: F1,12 = 3.25, p,0.1; ITI: F1,12 = 9.37,
p=0.001; Treatment6ITI: F1,12 = 0.25, NS; feeder latency, Treat-
ment: F1,12 = 1.17, NS; ITI: F1,12 = 0.61, NS; Treatment6ITI:
F1,12 = 0.20, NS). Importantly however, under these experimental
conditions D9-THC did not significantly affect premature respond-
ing, nor any other behavioral parameter in the 5-CSRTT.
Finally, the effects of D9-THC were tested in the DRT. As can be
seen in Figure 3c, acute challenges with D9-THC dose-dependently
reduced impulsive choice, with the highest dose (2 mg/kg) being
significantly different from vehicle (Treatment: F3,39 = 9.85,
p,0.001; Treatment6Delay: F12,156= 2.30, p=0.01). To verify that
the observed D9-THC effect was CB1 receptor-mediated, effects
of 2 mg/kg D9-THC alone and in combination with 1 mg/kg
SR141716A were tested next in the same group of rats. One animal
needed to be excluded from the analyses due to a high omission rate
(.80% of choice trials per delay block) under D9-THC alone
conditions. Results confirmed that the D9-THC-induced reduction
in impulsive choice was mediated by the CB1 receptor, as it was
completely abolished by pretreatment with SR141716A (Treatment:
F3,36 = 6.16, p=0.009, e=0.61; Treatment6Delay: F12,144= 1.29,
NS, e=0.77). Thus, it appears that although (endocannabinoid-
induced) CB1 receptor activation modulates the opposite effects of
amphetamine on impulsive action and impulsive choice, direct
stimulation of the receptor by administration of an exogenous
agonist only affects impulsive choice.
Discussion
This study provides evidence for an important role of the
cannabinoid CB1 receptor in modulating impulsive action as well
as impulsive choice and the effects of the psychostimulant drug
amphetamine thereon (Table 6). Previous studies showed that CB1
receptor antagonists with inverse agonistic properties increase
baseline inhibitory control in the 5-CSRTT [20,21]. The current
study extends these findings by showing that amphetamine-
induced decreases in inhibitory control, at least as measured in the
5-CSRTT, could be attenuated with the CB1 receptor antagonist/
inverse agonist SR141716A. Moreover, SR141716A fully pre-
vented the ameliorating effects of amphetamine on a different
form of impulsivity, that is impulsive choice as measured in the
DRT, while not affecting baseline behavior in the latter task.
Table 5. Effects of the CB1 receptor agonist D9-Tetrahydrocannabinol (THC) on measures of attentional function, compulsivity,
and motivation in the 5-CSRTT under conditions of normal or lengthened intertrial interval (ITI).
Treatment
(mg/kg) ITI (s) Accuracy (%)
Perseverative
responses
Correct response
latency (ms) Omissions Feeder latency (ms)
Vehicle 5 82.361.7 5.361.8 629616 9.362.2 16646114
THC 0.5 5 84.362.3 7.661.5 637620 11.261.4 17576155
Vehicle 7 75.462.5++ 2.660.4+ 625617 14.362.2++ 1467647
THC 0.5 7 74.362.9++ 1.860.6+ 626626 18.564.5++ 16906253
In total n = 13 animals were included in the analyses and data depict mean6SEM.
+p,0.05.
++p,0.005 compared to respective ITI = 5 s control.
doi:10.1371/journal.pone.0025856.t005
Table 6. Overview of the effects of CB1 receptor (ant)agonists on impulsive behavior found in this study.
CB1 receptor antagonist CB1 receptor agonist
SR141716A O-2050 (neutral) D9-THC
Impulsive action (5-CSRTT)
Baseline (ITI = 5 s) «* Q «
Baseline (ITI = 7 s) Q Q «
Amphetamine-induced (q) Q Q N.D.
Impulsive choice (DRT)
Baseline « « Q
Amphetamine-induced (Q) q q N.D.
Arrows indicate the direction of the effects of CB1 receptor (ant)agonists on impulsivity relative to baseline or amphetamine-induced levels of impulsivity, whereby
amphetamine alone increases and decreases impulsive action and choice as compared to baseline, respectively.
*SR141716A has under these conditions previously been found to reduce impulsivity in the 5-CSRTT (Pattij et al. 2007a). N.D. not determined.
doi:10.1371/journal.pone.0025856.t006
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Importantly, in both behavioral paradigms, the effects of
SR141716A were mimicked by the neutral CB1 receptor
antagonist O-2050 [49,57,58]. The current results are therefore
not compound-specific and can unlikely be attributed to inverse
agonism at the CB1 receptor [56], but rather reflect the effects of
blockade of CB1 receptor activation by endogenous cannabinoids.
Furthermore, we found that, at least under the current baseline
discounting curves with vehicle, direct CB1 receptor activation by
administration of the CB receptor agonist D9-THC reduced
impulsive choice without affecting impulsive action.
CB1 receptor activity modulates amphetamine-induced
impulsive action as well as impulsive choice
Psychostimulant drugs such as amphetamine are leading
prescription drugs to treat ADHD and maladaptive display of
impulsivity [26,27]. The acute effects of amphetamine on inhibitory
control [28–34] and impulsive choice [34–37] have been well
characterized in both humans and rodents, and are known to
depend on amphetamine’s ability to robustly enhance mesocortico-
limbic DA transmission [28,29,31–33,36,38,39]. However, other
neurotransmitter systems including the endogenous opioid and 5-
HT systems have also been shown to regulate certain aspects of
amphetamine-induced impulsivity [34,38,39]. Here, it was found
that blocking the CB1 receptor with either SR141716A or O-2050
alleviated amphetamine-induced inhibitory control deficits and
completely abolished amphetamine-induced decrements in impul-
sive choice, indicating that the endocannabinoid system plays a
critical role in the opposite effects of amphetamine on impulsive
action and impulsive choice. In addition, these findings add to
previous data pointing towards a modulatory role for CB1 receptors
in amphetamine’s effects on other behaviors including locomotor
activity, reward andmotivation, and relapse to drug seeking [42–47].
Exactly how the endocannabinoid system modulates amphet-
amine-induced behaviors remains as yet largely unknown. For
instance, data on the acute effects of amphetamine and other
psychostimulants on endocannabinoid levels in the brain is scarcely
available and rather inconclusive [40–42]. Since it is well known
that particularly mesocorticolimbic DA projections critically
regulate impulsive action and choice [28,29,31–33,36,38,39], it is
conceivable that CB1 receptor activity regulates (the effects of
amphetamine on) impulsive action and impulsive choice by
modulating mesocorticolimbic DA release. There is ample evidence
that CB1 receptor activity can indirectly modulate DA release into
brain areas such as the nucleus accumbens and medial prefrontal
cortex [45,60–63]. Similarly, there is evidence that DA receptor
activation can activate the endocannabinoid system [41,64,65].
Together, these findings suggest that interactions between the DA
and endocannabinoid systems, although being rather complex [65],
may be critical in regulating different aspects of impulsive behavior.
However, since CB1 receptor activity is capable of modulating
release of virtually all other neurotransmitters [12,13], it cannot be
ruled out that indirect effects of CB1 receptor (ant)agonists on other
neurotransmitter systems were responsible for the observed effects
on (amphetamine-induced) impulsivity. For instance, CB1 and m-
opioid receptors closely interact, and even the existence of CB1/m-
opioid receptor heterodimers in certain brain regions has been
suggested [58,66–69]. Interestingly, it was recently shown that m-
opioid receptors in the nucleus accumbens shell subregion are
critically involved in regulating amphetamine-induced changes in
inhibitory control, but not impulsive choice [34]. This could implicate
that CB1 and m-opioid receptors are located in one neuronal
population regulating inhibitory control, while being located in
distinct neuronal populations regulating impulsive choice. Accord-
ingly, we have recently observed that pretreatment with SR141716A
prevented the reduction in inhibitory control, but not the increase in
impulsive choice induced by the m-opioid receptor agonist morphine
(unpublished data). Together, our findings that CB1 receptor activity
is differentially involved in modulating impulsive action as measured
in the 5-CSRTT versus impulsive choice as measured in the DRT
provide further evidence for a fractionation of impulsive behavior at
the behavioral and neurochemical level [3,4,55,70].
CB1 receptor modulation of impulsive action
It should be noted that both SR141716A and O-2050 by
themselves did not affect premature responding in the 5-CSRTT
experiments with amphetamine. These findings are likely to reflect
a floor effect, i.e. the low baseline level of premature responding
presumably masked the enhancing effects of both compounds on
inhibitory control. Similarly, SR141716A did not affect premature
responding in a lateralized reaction time task, in which well-
trained animals make very few premature responses under
baseline conditions [71]. Moreover, when in the current study
task demands were changed by lengthening the intertrial interval
to increase the number of premature responses made, both
SR141716A and O-2050 reduced premature responding. These
findings clearly demonstrate that an endocannabinoid tone
underlies this behavioral response. In fact, the above described
observations combined with the current finding that CB1 receptor
antagonists alleviated the high levels of impulsive responding
induced by amphetamine suggest that the effects of CB1 receptor
antagonists on inhibitory control are rate-dependent. Consequent-
ly, reducing endocannabinoid transmission may only enhance
inhibitory control processes when the level of impulsive action is
sufficiently high, independent of whether impulsive action was
evoked pharmacologically or procedurally. Such a rate-dependent
behavioral profile would aid the clinical interest in compounds
that reduce endocannabinoid transmission, as specifically cohorts
of patients suffering from high levels of impulsivity, such as ADHD
patients and drug addicts, may then be expected to benefit from
this type of treatment. Importantly, lower doses of SR141716A
(1 mg/kg) and O-2050 (0.3 mg/kg) that already reduced (am-
phetamine-induced) premature responding did generally not affect
any other behavioral parameter in the 5-CSRTT, except for a
slight enhancement of accuracy by the lowest dose of O-2050, an
interesting effect that was previously also found with 0.3 mg/kg
SR141716A [21]. Parameters not affected by lower doses of both
CB1 receptor antagonists include those that can be interpreted as
indicators of somatomotor activity and food motivation, two
behavioral aspects that are well known to be influenced by CB1
receptor activity [72,73]. Particularly drug effects on food
motivation could have confounded the interpretation of the data
given the known positive relationship between CB1 receptor
activity and appetite [72] and the positive correlation between
food motivation and premature responding in the 5-CSRTT that
has been reported [74–76]. However, although this hypothesis
might explain the ameliorative effects of SR141716A and O-2050
on premature responding, it does not fit with the null effects of the
CB receptor agonists D9-THC (current study) and WIN55,212–2
[21] on this type of impulsive behavior. Moreover, reduced food
motivation has repeatedly been shown to result in increased
correct response latencies, omission rates, and to a lesser extent,
feeder latencies in the 5-CSRTT [74–76]. In the current study,
correct response latencies and omission rate were only increased
by doses of SR141716A and O-2050 that were higher than those
required to reduce premature responding. In addition, feeder
latencies were not affected by any drug treatment indicating that the
effects of both CB1 receptor antagonists were probably unrelated to
their anorectic properties. Another putative confounding factor
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might relate to the implementation of a fixed ITI duration in the
current study, as rats could have adapted a timing strategy to help
them predict the onset of stimulus presentations, a strategy that might
simultaneously decrease premature responding. Consequently, given
that both psychostimulants and cannabinoids are known to affect
timing behavior [14,77], the observed drug effects on premature
responding might have been a reflection of distorted timing abilities
rather than altered impulsivity. However, the observation that both
psychostimulants and CB receptor agonists result in an underesti-
mation of time [78,79] and only psychostimulant administration
results in increased premature responding in the 5-CSRTT argues
against such an explanation. In addition, it was recently found that
the CB1 receptor antagonist SLV330 reduced premature responding
in a version of the 5-CSRTT that incorporated ITI durations of
variable length rendering stimulus presentation unpredictable in time
[20]. Similarly, amphetamine has been shown to increase premature
responding in a 5-CSRTT with variable ITI durations [80], although
in this particular study premature responses remained unpunished
hampering the interpretation of this parameter as a readout for
inhibitory control. Moreover, others have reported a reduction in
impulsivity following amphetamine administration under similar
conditions [81]. Altogether, these findings do not support a major role
for altered time perception in the drug-induced changes in impulsivity
observed in the current study. Collectively, although non-specific
behavioral effects of the drugs used in this study cannot be ruled out
completely, such effects are unlikely to have fully accounted for the
effects of these compounds on impulsivity.
Considering the apparent important role of CB1 receptor
activity in (amphetamine-induced) inhibitory control deficits, it
was somewhat surprising that the CB receptor agonist D9-THC
did not affect premature responding in the 5-CSRTT. Similar
results were previously obtained for another synthetic CB receptor
agonist, WIN55,212–2 [21]. Collectively, these data suggest that
CB1 receptors regulating inhibitory control may already be
maximally activated, for instance, due to excessive task-induced
release of endogenous cannabinoids, thereby occluding effects of
exogenous CB receptor agonists on impulsivity. Alternatively,
distinct populations of CB1 receptors in the brain may exert
opposite effects on premature responding. In the latter scenario,
stimulation of all CB1 receptors by systemic administration of an
agonist would have no net effect. Future experiments employing
intracranial infusion of CB1 receptor agonists as well as inhibitors
of endocannabinoid synthesis and hydrolysis may shed more light
on this issue. In particular, such experiments including intracranial
infusion of CB1 receptor antagonists will aid elucidating the
anatomical locus where CB1 receptors modulate impulsivity.
Considering the critical role of the prefrontal cortex and nucleus
accumbens in regulating this behavior [3,4,55] and the high
abundance of CB1 receptors in these brain areas [10,11], these
brain areas are likely candidates. However, a role for CB1
receptors in brain areas such as the ventral tegmental area, dorsal
raphe nucleus and locus coeruleus cannot be ruled out at this
point. Importantly, CB1 receptors can modulate the efferent
output of these brain regions, thereby controlling monoaminergic
input to brain areas including the prefrontal cortex and nucleus
accumbens [82–84].
CB1 receptor modulation of impulsive choice
In contrast to the absence of an effect ofD9-THC in the 5-CSRTT,
D9-THC decreased impulsivity in the DRT, an effect that was
antagonized by SR141716A, hence, was CB1 receptor-dependent.
Together with the finding that CB1 receptor antagonists completely
abolished amphetamine-induced decrements in impulsive choice
without affecting baseline impulsive choice behavior, this suggests that
although CB1 receptors are not involved in mediating baseline
impulsive choice, targeted CB1 receptor activation could be used to
alleviate problems with delay aversion. In contrast, acute D9-THC
administration in healthy volunteers does not seem to affect impulsive
choice in a DRT [17]. However, as discussed before [85], fundamental
differences between the human and rodent version of the DRT may
account for this discrepancy. The current findings withD9-THC in the
DRT also contrast the previously observed lack of effect of
WIN55,212-2 in this task [21]. This inconsistency may be related to
the fact that both agonists have completely dissimilar chemical
structures and consequently differ in e.g. efficacy and binding profile at
the CB1 receptor [59,86]. To clarify this issue, the effects of other CB1
receptor agonists should be tested in the DRT. Particularly the effects
of exogenous administration of the endocannabinoid anandamide
would be interesting in this respect, since anandamide resembles
D9-THC in being a partial CB1 receptor agonist [87] and ADHD
patients were found to have decreased anandamide degradation as
compared to healthy control subjects [25].
Concluding remarks
The current results indicate an important, though complex role
for CB1 receptor activity in regulating impulsive actions and
impulsive choice as well as the opposite effects of amphetamine on
both aspects of impulsivity. These data extend previous findings on
the role of CB1 receptors in impulsive behavior, including clinical
findings linking polymorphisms in the CB1 receptor gene (CNR1
gene) to impulsivity [22] and the development of ADHD [23,24].
Although the mechanism underlying CB1 receptor modulation of
impulsivity still remains unknown, and the endogenous ligands
involved elusive, the CB1 receptor may be an interesting novel
target for pharmacotherapies to treat maladaptive impulsivity.
According to the dual pathway model for the development of
ADHD [88,89], our data would then suggest that patients
suffering from a primarily motivational, delay aversion subtype
of ADHD may benefit from enhanced CB1 receptor activation,
whereas on the other hand patients whose disorder is more related
to poor inhibitory control may benefit from reduced CB1 receptor
activity. Future studies will have to explore under which exact
conditions CB1 receptor-targeted drugs can be helpful to treat
maladaptive impulsivity.
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